Showing results (121-130 of 244) with videos related to

Sort By:
Pageof 25
Annals of Surgical Oncology|June 23, 2026
Association Between Axillary Surgical Management and Survival for Patients With De Novo Metastatic Breast CancerEmilie Laude, Celian Guyon, Louna Mossino Diaz, et al.
Anticancer Research|November 2, 2010
Concordant analysis of KRAS status in primary colon carcinoma and matched metastasisPascale Mariani, Marick Lae, Armelle Degeorges, et al.
Plos One|December 20, 2015
Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant ChemotherapyHélène Bonsang-Kitzis, Léonor Chaltier, Lisa Belin, et al.
Plos One|April 25, 2012
Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinomaFabien Reyal, Marc A Bollet, Martial Caly, et al.
Breast Cancer Research : BCR|September 15, 2020
Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapyLuc Cabel, Dan Rosenblum, Florence Lerebours, et al.
Bulletin Du Cancer|June 6, 2012
[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France]Anne-Claire Hardy-Bessard, Rémy Delva, Xavier Pivot, et al.
Future Oncology (London, England)|April 9, 2024
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancerValentina Guarneri, José Luís Passos Coelho, Francois P Duhoux, et al.
Plos One|September 1, 2012
Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patientsMaura Campitelli, Emmanuelle Jeannot, Martine Peter, et al.
Breast Cancer (Tokyo, Japan)|April 10, 2024
Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastasesAlexandre De Moura, Delphine Loirat, Sarah Vaillant, et al.
The Lancet. Oncology|March 2, 2012
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 studyJean-Yves Pierga, Thierry Petit, Thierry Delozier, et al.
Pageof 25